SCHEMBL17047362

SCHEMBL17047362

O=S(=O)(N1CCCCC1)N1CCC(Cl)(Cl)C1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.54
KMT2A Q03164 5/20 0.52
TSHR P16473 3/20 0.52
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 7/20 0.41
MEN1 O00255 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
MAPT P10636 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
HTT P42858 1/20 0.38
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
MCOLN3 Q8TDD5 2/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29905605 0.75 POLB (0.93) POLBKMT2ATSHRKDM4EALDH1A1
SCHEMBL5280013 0.75 POLB (0.93) POLBKMT2ATSHRKDM4EALDH1A1
SCHEMBL1546827 0.72 POLB (0.87) POLBKMT2ATSHRKDM4EALDH1A1
SCHEMBL21361650 0.68 KDM4E (0.60) POLBKMT2ATSHRKDM4EALDH1A1
SCHEMBL5314300 0.67 KMT2A (0.81) POLBKMT2ATSHRKDM4EALDH1A1
SCHEMBL30392490 0.63 TSHR (0.95) POLBKMT2ATSHRKDM4EALDH1A1
SCHEMBL9028142 0.63 POLB (0.67) POLBKMT2ATSHRKDM4EALDH1A1
SCHEMBL3176249 0.63 KDM4E (1.00) POLBKMT2ATSHRKDM4EALDH1A1
SCHEMBL6962582 0.63 POLB (0.67) POLBKMT2ATSHRKDM4EALDH1A1
SCHEMBL417152 0.62 CA1 (0.58) POLBKMT2ATSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015130445-A1 QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2015-09-03 WO disclosed
WO-2015130444-A1 QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2015-09-03 WO disclosed